These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9114082)

  • 1. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
    Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
    Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
    Utech CI; Young CS; Winter PF
    Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
    Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
    Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
    Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
    Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
    Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
    Barranger E; Grahek D; Antoine M; Montravers F; Talbot JN; Uzan S
    Ann Surg Oncol; 2003 Jul; 10(6):622-7. PubMed ID: 12839846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
    Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
    J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
    Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
    Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
    van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
    Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
    Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
    Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
    Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
    Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.